Carotid Artery Disease in Diabetic Patients: Contemporary Perspectives

Nadeem Ahmed Siddiqui1*, Asad Moosa1, Fareed Shaikh1, Waryam Saleh1 and Avgenie Efthymios2

1Division of Vascular Surgery, Aga Khan University Hospital, Karachi, Pakistan
2Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Abstract

Carotid artery disease is a significant contributor of diabetic patients’ morbidity and mortality driven by its strong association with ischemic stroke. The link between carotid atherosclerosis and cerebrovascular or coronary artery disease is otherwise well established pointing to a high risk patient. This link gets particularly important in diabetic patients who demonstrate high rates of silent cardiovascular events, as a means of early detection of underlying atherosclerotic disease. Carotid ultrasonography now allows clinicians to visualize the characteristics of the carotid wall and lumen surfaces, to quantify the severity of local and systemic atherosclerosis and better guide the intensity of primary and secondary prevention strategies. Carotid revascularization remains the standard of care for high grade stenosis and while higher perioperative events and restenosis rates may be anticipated the benefits derived from the procedure still outweigh the risks. Current guidelines recommend carotid endarterectomy as a gold standard procedure; however carotid artery stenting can be a valid alternative in high medical risk symptomatic diabetic patients. Optimal glycemic control and confounding risk factor management can ameliorate short and longer term adverse events.

Keywords: Carotid artery disease; Carotid atherosclerosis; Carotid plaque; Carotid intima media thickness; Carotid endarterectomy; Carotid stenting; Carotid restenosis

Introduction

Cardiovascular diseases remain one of the main causes of morbidity and mortality in diabetic patients manifesting as silent and eventually clinically significant coronary, cerebrovascular and limb vascular events. While the association of diabetes with extracranial carotid atherosclerosis was a subject of debate in the recent past, further studies have now confirmed its positive independent role in the development of carotid disease and subsequent related events like transient ischemic attacks and ischemic stroke [1-4]. Alongside, carotid disease progression through ultrasonography is currently widely suggested as a means of screening global atherosclerotic changes in type 2 diabetes [5-7]. The current review summarizes the distinct characteristics of carotid atherosclerosis and contemporary management in diabetic patients.

Epidemiology

Patients with type 2 diabetes have thicker and stiffer carotid arteries and are more likely to suffer from cerebrovascular events [1-8,9]. Carotid plaques are identified in approximately 30% of newly diagnosed type 2 diabetic patients and this percentage doubles within a 2 year follow up [10,11]. The respective rate can be as high as 50-70% in patients with known diabetes, however the severe forms of the disease (ICAS stenosis >60%) are only seen in approximately 5% of the patients [10-12]. The atherosclerotic burden seems to be different between the left and right carotid artery, with the left being more susceptible to carotid atherosclerosis, potentially because the left carotid artery is a first order branch of the aorta receiving a higher hemodynamic stress [13-16].

Diabetes increases the risk of stroke by 1.8-6 folds [1]. Alongside, diabetes prevalence ranges between 21-69% among patients with acute ischemic stroke, a 3 fold higher rate when compared to matched controls [2,3,17,18]. These patients are being anticipated to have higher incidence of post stroke mortality, dependency state and recurrent stroke compared to non-diabetics [19-23]. While there are no clear gender differences, ethnicity is associated with different stroke rates in diabetic patients [24-27]. Over the past years, the risk of stroke has declined significantly in black population as compared to a stable incidence in white population [26]. Similar results were also reported in the Baltimore-Washington Cooperative Young Stroke Study, which demonstrated that the presence of diabetes markedly increased the odds ratio for stroke from 3.3% in the black population to as high as 23.1% in the white population [27].

Physiology of Carotid Atherosclerosis in Diabetes

Understanding plaque morphology and vulnerability is critical for the prognosis of carotid disease. Atherosclerotic plaques prone to rupture, referred as vulnerable plaques, are characterized by a lipid-rich necrotic core and a thin fibrous cap, result of a high inflammatory activity. This further relates to increased vascularization, loss of vascular smooth muscle cells (VSMCs) and degradation of structural components (e.g. collagen) by matrix metalloproteinases (MMPs). The mechanisms responsible for the increased cardiovascular risk in diabetes remain to be fully understood, but much attention has pointed to the role of inflammation, vascularization and impaired fibrous repair capacity within the plaque.

Carotid atherosclerosis is associated with chronic low-grade systemic inflammation as assessed by serum elevated C-reactive protein and fibrinogen [28]. These inflammatory biomarkers are even more elevated in diabetic patients [29]. Studies on coronaries have shown that plaques from subjects with type 2 diabetes have more inflammatory cells and a greater necrotic core [30,31]. It has also been demonstrated that carotid plaques from diabetic patients with...
symptomatic atherosclerotic disease have a higher density of vessels and increased VEGFR-2 expression in the plaque shoulder regions when compared to non-diabetics [32].

According to other studies, diabetic plaques may be more prone to rupture not necessarily due to increased vascular inflammation but due to impaired repair responses [33]. Edsfeldt et al. demonstrated that inflammatory markers (macrophage inflammatory protein-1β, IL-6, MMP-1, MMP-9, TIMP-1) are in fact not associated with diabetes; however, carotid plaques from diabetic subjects have reduced content of fibrous connective tissue proteins required to maintain plaque stability (extra cellular matrix proteins, collagen and elastin) as well as lower levels of factors known to promote the formation of fibrous tissue such as PDGF (stimulates vascular smooth muscle cell proliferation and synthesis of extracellular matrix proteins) and MMP-2 (degrades collagen IV, a key regulatory step for conversion of VSMC into the synthetic, proliferative repair phenotype required for induction of intima repair response) [33]. This could make diabetic carotid plaques more prone to rupture, requiring a significantly lower level of inflammatory activation to cause symptoms. Esposito et al. confirmed through MRI imaging that diabetes is otherwise associated with higher risk lesions matching vulnerable carotid plaque characteristics [34].

**Carotid Intima Media Thickness in Diabetes**

The close association between carotid atherosclerosis and cerebrovascular or coronary artery disease is well established. Carotid ultrasonography has allowed clinicians to visualize the characteristics of the carotid wall and lumen surfaces to quantify the severity of atherosclerosis. This becomes particularly important in diabetic patients who show high rates of silent myocardial events [35]. Carotid intima-media thickness (CIMT) measured with B-mode ultrasound has been confirmed to be a quantitative and reproducible measure of atherosclerosis in other vascular beds and a predictor of cardiovascular events [36,37]. CIMT at baseline was a strong predictor of non-fatal coronary heart disease in a study of 287 Japanese diabetic patients followed up for 3 years [38]. More recently similar results were reproduced confirming that CIMT could be a predictor for the development of cardiovascular events in a study of 469 asymptomatic type 2 diabetic patients followed up for 6.1 years [39]. Other studies however have indicated that the presence of carotid plaques may be a more accurate surrogate marker of generalized atherosclerosis [10,39]. Irrespective, it is evident that carotid ultrasound in diabetic patients, to assess the CIMT and/or presence of carotid plaques, is a valuable tool to screen their atherosclerotic burden and guide appropriate medical treatment. CIMT measurement, however, has not been widely accepted as it still has several limitations (including establishing a reference range and comparisons between measurements carried out in different and even the same unit), thus further studies are awaited.

**Medical Management of Carotid Disease in Diabetes**

Optimal medical treatment for carotid artery disease is currently well established both for primary and secondary prevention, and includes atherosclerotic risk factor management, antiplatelets and lipid lowering therapies. Glycemic control in diabetic patients with carotid disease (or any other atherosclerotic disease) is a crucial strategy to prevent disease progression and/or symptomatic conversion, however intensive therapies targeting HbA1C<6% did not show reduction in stroke rates [40,41]. Therefore targeting HbA1C of 7% is currently recommended [42]. Insulin sensitizers seem to be superior over insulin secretagogues. In the 10-year follow up of United Kingdom Prospective Diabetes Study (UKPDS) the metformin treated arm had 33% reduction in myocardial infarction and 27% reduction in all-cause mortality, both significantly more than that in the patients in the sulfonylurea [43,44].

Blood pressure control seems to be more important than aggressive glycemic control in stroke risk reduction as demonstrated by the UK-TIA Trial [45]. Randomized clinical trial evidence among high-risk diabetic patients indicates that there is no benefit in achieving an aggressive systolic blood pressure (SBP) of <120 versus <140 mm Hg [46]. Current recommendation is that hypertensive patients (>140/90 mmHg), should start pharmacotherapy in addition to lifestyle modification to achieve SBP <140 mmHg and diastolic blood pressure (DBP) <90 mmHg. Lower targets (SBP <130 mmHg, DBP<80 mmHg) can be appropriate in certain individuals, such as younger patients if they can be achieved without undue treatment burden [47].

Statin therapy, given their anti-inflammatory pleiotropic effects, can be beneficial for diabetes even if cholesterol levels are not elevated [48,49]. Statin therapy is recommended for all patients with diabetes and it should be of high intensity for those with known cerebrovascular disease (LDL-C<70 mg/dL) [47].

Overall, intensive management of all cardiovascular risk factors can result in a net benefit of diabetic patients with carotid atherosclerosis. As shown in a recent prospective study of patients with type 2 diabetes and at least two insufficiently treated cardiovascular risk factors (e.g., HbA1C>7.5%, LDL-C>120 mg/dl or blood pressure>140/90 mmHg), intensive treatment to reach targets of HbA1C ≤ 6.5%, LDL-C<100 mg/dl and blood pressure ≤130/80 mmHg resulted in a significant regression in mean CIMT at 2 years [50].

**Carotid Revascularization in Diabetes**

Carotid endarterectomy (CEA) is considered the gold standard in symptomatic patients with >50% internal carotid artery stenosis and is recommended in asymptomatic internal carotid artery stenosis >70% provided that perioperative risk of stroke and death is less than 3% and the patient has an estimated survival of at least 5 years [49,51]. Carotid artery stenting (CAS) has been associated with higher perioperative risk of stroke and is currently recommended as an alternative for symptomatic patients at high medical or anatomic risk [49,51]. Several studies have demonstrated a mild to moderate effect of diabetes on the 30-day risk of stroke and death after carotid revascularization, as well as a long-term effect on mortality and restenosis; some suggesting that it may not be diabetes itself but the co-existing cardiovascular risk profile.

In one of the largest CEA series (>13,000 CEAs, VA database (NSQIP)), the presence of insulin-dependent diabetes was the strongest independent patient risk factor for an adverse outcome on the basis of an increased risk of cardiac events and death [52]. In another large series assessing the outcomes of 4,305 carotid endarterectomies (883 diabetics vs. 3422 non diabetics) diabetics had a higher 30-day mortality (OR 3.5, P=0.002) but no difference in cardiac or neurological events [53]. Combined perioperative stroke and death was higher in diabetics (2% vs. 0.9%, P=0.006) and the significance was sustained in multivariate analysis. Follow up showed no differences between the two groups in the estimated 7-year ipsilateral and overall stroke and mortality rates. Insulin dependence showed no early or late associated risks. Similar results were reported in another series reviewing 2,196 carotid interventions (1,196 CEA, 1,080 CAS); diabetes was associated with a threefold risk of 30-day post-CEA stroke and death (OR 2.8, 95% CI 1.05-7.60, P=0.04) [54]. However, in the CAS group, neither diabetes nor insulin could predict outcomes. Excluding the perioperative period,
the 6-year stroke and death rates were similar for either procedure irrespective of diabetic status. The authors suggested that CAS may be preferred in selected diabetic patients, given the higher perioperative risks of CEA; however further evidence is needed to support this.

Overall, diabetic patients undergoing CEA should be anticipated to experience slightly higher perioperative events, partly related to preexisting silent myocardial ischemia. This perioperative risk though remains largely below the limits recommended by published guidelines, confirming the feasibility and safety of CEA in diabetic patients. A thorough preoperative cardiac evaluation and risk factor control could ameliorate these events, but diabetic patients with multiple other comorbidities should be also considered for CAS.

**Restenosis after carotid revascularization**

Carotid restenosis is an important parameter of the long term outcomes after CEA or CAS that could limit their long-term efficacy as it can lead to recurrent ischemic events. Carotid restenosis is generally attributed to neointimal hyperplasia when occurring within the first 2 years, or to recurrence of underlying atherosclerotic disease thereafter [55,56]. The secondary analysis of the most recent and largest randomized controlled trial “Carotid Revascularization Endarterectomy vs. Stenting Trial” (CREST) comparing outcomes of CAS vs. CEA in 2502 patients reported a >70% restenosis rate of 6% after CEA, which was comparable with the 6.3% restenosis rate after CEA at 2 years [57]. It was demonstrated that after adjusting for age, sex and symptomatic status, diabetes was a predictor of restenosis at 2 years for both CEA (HR 2.35, 95% CI 1.43-3.86) and CAS (HR 2.44, 95% CI 1.46-4.08). Previous large single-institution studies of CEA and CAS and studies of coronary arteries have implied that diabetes and poor preprocedural glycemic control are risk factors for recurrent stenosis [54,56-60]. It is speculated that the presence of diabetes can both increase neointimal hyperplasia after arterial injury and accelerate the growth of new carotid plaques at the site of CEA. The presence of perioculudal hyperglycaemia may otherwise induce an inflammatory and oxidative stress burden on the vessel wall that accelerates the early phase cascade the restenosis [60].

**Conclusion**

Carotid atherosclerosis is a significant contributor of diabetic patients’ morbidity and mortality. Surveillance for carotid artery disease, even at its early stages, can point patients at high risk for cardiovascular events and guide the intensity of primary and secondary prevention strategies, as well as the optimal management, medical, surgical or endovascular. Higher rates of postoperative adverse events and higher rates of long term carotid restenosis should be anticipated in diabetic patients after carotid revascularization.

**References**


ISSN: 2165-7831

Page 3 of 4

Volume 9 • Issue 1 • 1000238 J Blood Lymph, an open access journal

ISPOR 1098-3015, S101-S105.


